KURA ONCOLOGY: 'STRONG BUY': ZIFTOMENIB AML EXPANSIONS WITH DIFFERENT REGIMENS COULD BOOST KOMZIFTI'S PROSPECTS - SEEKINGALPHA

Ziftomenib AML regimen expansions could boost Komzifti prospects, per Seeking Alpha's Strong Buy.